pharmaphorum

Company Profile: Recursion

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
pharmaphorum

Recursion, Exscientia, and AI drug discovery’s moment of truth

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
The New York Times

Silicon Valley Wants to Build A.I. That Can Improve A.I. on Its Own

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...
TechCrunch

AI chip startup Ricursive hits $4B valuation 2 months after launch

Ricursive Intelligence, a startup building an AI system to design and automatically improve AI chips, has raised $300 million at a $4 billion valuation. The company said Monday the round was led by ...
Investopedia

Deal Flow: Navigating Business Sentiment in Venture Capital

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
Investopedia

Chart of Accounts (COA): Definition, How It Works, and Example

Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. Amy is an ACA and the CEO and founder ...